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Introduction {#s1}
============

*Ocimum basilicum* L. (Lamiaceae) or sweet basil is a popular culinary and ornamental herb, used for its medicinal properties in Asia and Africa. The herb is native to India, Southeast Asia, New Guinea and many countries in Africa, and a famous ingredient in Ayurveda, Unani and Siddha system of traditional medicine. The distinct characteristic aroma, chemical composition and biological activity of the basil essential oil depend on factors such as morphological variability, topography and other environmental factors ([@B70]). It is used as an Indian traditional medicine in the supplementary treatment of asthma, diabetes and stress ([@B24]). Ethnic communities in Africa and India use whole basil plant decoctions in patients with tuberculosis (TB) ([@B79]; [@B25]). The volatile oil of basil comprises of components such as eugenol ([@B1]), geraniol, eucalyptol, fenchone, and estragole ([@B65]), some of these compounds being used as a local antiseptic and anaesthetic ([@B47]). Previous studies have shown anti-TB activity of the crude methanolic extract from the aerial parts (leaves, fruits, and flowers) of basil ([@B85]). *In vitro* studies have shown that phytocompounds in the oil have potent antioxidant, antiviral, and antimicrobial properties, and have been tested in cancer treatment ([@B15]; [@B11]; [@B61]; [@B19]). Esters and amides synthesized from dichloromethane extract of basil have been tested *in vitro* using an HIV-1 Reverse Transcriptase (RT)-associated RNase H inhibition assay; tetradecyl ferulate inhibited RNase H with IC~50~ 12.4 μM and N-oleylcaffeamide strongly inhibited the RT-associated activity of ribonuclease H and DNA polymerase ([@B88]).

Due to the use of this herb as a common spice as well as its availability in the pharmacies as a liquid/powder extract and pure essential oils for various health conditions, there is a potential for concomitant administration with conventional drugs, hence potential for herb-drug interactions (HDI). The phytoconstituents within the herbs can potentially inhibit or induce the activity of drug-metabolizing enzymes and transport proteins. Recent studies have examined the inhibitory and inducing effects of various West African, Chinese, South American and Indian herbs and their extracts or formulations, such as *Uncaria tomentosa* (Willd. ex Schult.) DC. ([@B103]), *Astragalus mongholicus* Bunge ([@B56]), *Momordica charantia* L. ([@B31]), and *Curcuma longa* L. and *Phyllanthus emblica* L. ([@B84]), on cytochrome P450 activities.

Previous studies showed the inhibitory effect of the methanolic extract of basil on the activity of CYP2D6, CYP3A4, CYP3A5, and CYP3A7 ([@B68]). Another study using MROD assay (7-methoxyresorufin dealkylation) showed the inhibitory effect of methanol-dibutyl ether extract from basil on the CYP1A2 mediated metabolism of methoxyresorufin to its fluorescent metabolite resorufin ([@B50]). Other interactions reported include the induction of CYP2A6, 2C9, 2D6 and 2E1 by safrole and estragole present in basil extracts, to form carcinogenic 1′-hydroxy metabolites ([@B49]; [@B50]).

Systematic review studies have reported the high HIV/TB-burden in African countries where coinfected patients are treated with efavirenz and rifampicin-isoniazid regimens ([@B5]). The current WHO TB-HIV treatment guideline for the effective dosage of efavirenz in patients during concomitant rifampicin-based anti-TB therapy is 600 mg/day; this being confirmed in previous studies in the sub-Saharan Africa ([@B8]; [@B40]). However, with the possibility of drug-drug interactions involving CYP2B6 and 3A4, it is necessary to analyze if the coadministration of basil in such scenarios can cause clinically significant herb-drug interactions. For example, artemisinin extract obtained from the Chinese herb *Artemisia annua* L., used in malarial treatment and metabolized by CYP2B6 and 3A4, has been studied to cause potential toxicities *in vitro* when coadministered with drugs such as orphenadrine ([@B43]), which could be attributed to CYP2B6/3A4 inhibition and incomplete metabolism.

CYP2B6 predominantly metabolizes efavirenz to its primary metabolite 8-hydroxy efavirenz with the involvement of CYP3A to a lesser extent, and CYP2A6-mediated metabolism to 7-Hydroxy efavirenz. CYP2B6 plays a critical role in efavirenz metabolism, forming the secondary metabolite 8,14-dihydroxy efavirenz from 8-hydroxy efavirenz ([@B102]). Previous studies have shown the significance of various factors such as ethnicity and pharmacogenetic variations (CYP2B6 alleles) in influencing the efavirenz pharmacokinetics in HIV/AIDS patients in Africa ([@B92]; [@B67]). CYP3A4 catalyzed metabolism pathway devises a major route for elimination of many drugs and the induction or the inhibition of its expression by other drugs or herbs is often implicated in clinically significant interactions. Many drug-drug interaction (DDI) studies related to drug-resistant TB and TB/HIV co-infection analyzed the involvement of CYP3A4 as a key enzyme ([@B58]).

Research has been done to explore the effects of rifampicin as an inducer in herb and drug-drug interaction studies; however the effect of HDI on the β-esterase-mediated metabolism pathway of rifampicin to 25-*O*-desacetyl rifampicin has not been investigated. Assessing its metabolism profile and the potential of the herbs to induce or inhibit the formation of 25-*O*-desacetyl rifampicin is critical, because if the normal pharmacokinetics of this metabolism pathway is affected, incomplete metabolism of rifampicin may result in toxicity and fatal poisoning ([@B14]; [@B89]). Case studies have reported reversible hepatic, renal damage and fatal poising with the ingestion of 9--12 g and 14--15 g of rifampicin ([@B73]; [@B14]; [@B62]). The high burden of rifampicin toxicities among HIV/TB co-infected patients ([@B38]; [@B105]) often contributes to morbidity and mortality; anti-TB drug induced liver injury in China being an example ([@B83]).

This research study investigated the relevant phyto-compounds present in the dried leaves and inflorescence of *O. basilicum* using various biochemical tests, LC-MS and their interactions with CYP2B6, 3A4, and rifampicin metabolism (β-esterases) in HLM and HepG2 cells. The potential clinical relevance of the findings was assessed by *in vivo* predictions of the inhibitory potential of the extracts in the GIT.

Materials and Methods {#s2}
=====================

Reagents and Chemicals {#s2_1}
----------------------

The biochemical tests were performed using the following reagents:

-   Dilute ammonia solution (Hopkin and Williams, England).

-   Vanillin reagent: 1% vanillin in 70% concentrated sulphuric acid (BDH Chemicals, England).

-   Wagner's reagent: 2 g of iodine (BDH Chemicals, England) and 6 g of potassium iodide (Merck, Germany) dissolved in 100 ml of water.

-   Neutral ferric chloride solution, 0.1% ferric chloride solution (Sigma-Aldrich, Steinheim, Germany).

-   10% Sodium hydroxide solution (BDH Chemicals, England).

-   Magnesium solution (Hopkin and Williams, England).

-   Glacial acetic acid, concentrated sulphuric acid (BDH Chemicals, England), ferric chloride (Sigma-Aldrich, Germany).

-   Chloroform, acetic anhydride (BDH Chemicals, England).

Efavirenz, rifampicin, ticlopidine and nelfinavir mesylate hydrate were obtained from Sigma-Aldrich (Steinheim, Germany), while pure 8-hydroxy efavirenz, 25-*O*-desacetyl rifampicin and neostigmine methyl sulphate were obtained from Clearsynth Labs Ltd. (Mumbai, India).

HPLC-grade methanol (Sigma-Aldrich, Germany), ethanol (Merck KGaA, Darmstadt, Germany), purified HPLC-grade water (Adrona B30 purification systems, Adrona SIA, Latvia), and ethyl acetate (BDH Chemicals, England) were used for the extractions and LC-MS mobile phase solvents.

For the HLM inhibition assays, magnesium chloride, glucose-6-phosphate sodium salt, glucose-6-phosphate dehydrogenase, phosphate buffer solution 1 M, and β-nicotinamide adenine dinucleotide phosphate hydrate (NADPH) were purchased from Sigma-Aldrich (Steinheim, Germany). For the induction assays, microtiter 96--well U--bottom plates from Tarsons Products Pvt. Ltd., Kolkata, India were used. 25 cm^2^ cell culture flasks were purchased from Corning^®^ Inc. (New York, US). MTT (thiazolyl blue tetrazolium bromide), phosphate buffered saline pH 7.4 (PBS), nutrient mixture F-12 Ham, EDTA, Dulbecco's modified Eagle's medium---high glucose (DMEM), trypsin, and the antibiotics for cell culture were purchased from HiMedia Laboratories (Mumbai, India). Gibco™ Fetal bovine serum (FBS) was purchased from Thermofisher Scientific (MA, USA). Tri-Xtract™ for the RNA isolation was purchased from G-Biosciences Ltd. (MO, US). Dimethyl sulfoxide (DMSO) was purchased from Finar Ltd. (Gujarat, India).

Plant Material {#s2_2}
--------------

The dried leaves and inflorescence of *O. basilicum* (Lamiaceae) were obtained in powdered and packed form, from Pharma Germania, Benoni, South Africa (Certificate of Analysis\# PFI-2645/08/2014, country of origin---Egypt).

Preparation of Plant Extracts {#s2_3}
-----------------------------

The dried leaves and inflorescence of *O. basilicum* were weighed (4 g) andextracted exhaustively after boiling with purified water (Adrona B30, up to 500 ml for 9 days). Forthe other solvent extractions, 4 g of the herb was added to methanol, ethanol and ethyl acetate(HPLC grade), and extracted exhaustively using mechanical agitation (up to 500 ml for 9 days). The extract was filtered and evaporated at 50°C using a concentrator-freeze drier (miVac, England) to complete dryness and stored in sealed glass containers in a vacuum desiccator, at 2--4 °C. Percentage of yield was calculated as per equation (2.3.1):
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Where, W~1~ is net weight of basil extract in grams after extraction and W~2~ is total weight of dried basil in grams taken for extraction.

Human Liver Microsomes and HepG2 Cell Lines {#s2_4}
-------------------------------------------

The HLM assays were performed using H0630---pooled human liver microsomes (mixed gender, protein concentration: 20 mg/ml) obtained from Sekisui Xenotech LLC (Kansas, USA). HepG2 (human hepatocellular carcinoma cells) cell line was procured from National Centre for Cell Sciences (NCCS), Cell Repository, Pune, India.

Analytical Instrumentation Settings {#s2_5}
-----------------------------------

LC-MS phytochemical fingerprinting analyses were performed using Waters Synapt G2 Quadrupole time-of-flight (QTOF) mass spectrometer (MS) connected to a Waters Acquity ultra-performance liquid chromatograph (UPLC) (Waters, Milford, MA, USA). Waters HSS T3, 2.1 × 100 mm, 1.7 μm column was used for the separation. A cone voltage of 15 V for both positive and negative mode ionizations, desolvation temperature of 275°C, and desolvation gas at 650 L/h ([@B90]). Data were acquired by scanning all extracts, from 150 to 1,500 *m/z* in resolution mode as well as in MS^E^ mode. In MS^E^ mode two channels of MS data were acquired, one used low collision energy (4 V) and the second one at collision energy ramp in the range 40−100 V, to obtain fragmentation data as well. Sodium formate was used to calibrate the UPLC-MS and leucine enkaphalin was used as reference mass (lock mass) for accuracy in mass determination; Waters HSS T3, 2.1 × 100 mm, 1.7 μm column was used for the separation.

For the HLM assay sample analyses, Waters Alliance 2695 HPLC system coupled with 2996 PDA detector was used. A C-18 Phenomenex-Evo column (150 x 2.6 mm, 3.5 μm) and a C-18 Phenomenex Luna column (150 x 4.6 mm, 5 μm) was used for separating efavirenz and 8-hydroxy efavirenz, and rifampicin and its metabolite, respectively. PDA wavelength was set at 245 nm for efavirenz assay sample analyses and 254 n for rifampicin assay sample analyses. The gradient solvents elution program was set as (Time*~min~*~/~% solution B) at 0/10, 5/80, 10/95, 9/80, and 11.5/10 ([@B99]; [@B55]).

AE-series inverted microscope (Motic Asia, Hong Kong) was used for tissue culture inspection. BioTek Epoch automated microplate reader with Gen5 2005 software v1.10.8 (BioTek Instruments, Inc. USA) was used for plate incubations and readings. Polymerase chain reactions were done using the MJ mini thermocycler (Bio Rad, Hercules, CA, USA).

Data Analysis {#s2_6}
-------------

Non-linear regression graph plots for determining the IC~50~ and statistical analyses were performed using GraphPad Software Inc. (San Diego, CA; [www.graphpad.com](www.graphpad.com)) Prism version 5.00 for Windows, was used.

For gel electrophoresis applications, inGenius---gel documentation system comprising of GeneTools analysis software (Syngene, MD, USA) was used for digital imaging and relative sample expression levels.

Biochemical Phyto-Profiling {#s2_7}
---------------------------

The following standard methodologies were followed for biochemical tests ([@B42]; [@B78]; [@B45]):

1.  Test for alkaloids

    a.  Harborne Test

        About 170 μl of dilute ammonia solution was added to 200 μl of test solution of each basil extract followed by addition of few drops of concentrated sulphuric acid. Formation of yellow coloration indicated the presence of alkaloids.

    b.  Wagner's Test

        To 500 μl of plant extract solution, equal amount of Wagner's reagent was added. The test result was observed. Formation of reddish-brown coloration ascertained the presence of alkaloids.

2.  Test for saponins

    About 200 μl of the plant extract was mixed with 170 μl of pure distilled water and shaken vigorously for a stable persistent froth, which indicated the presence of saponins.

3.  Test for phenols

    To 200 μl of the plant extract solution, 150 μl of neutral ferric chloride solution was added. Formation of greenish colour showed the presence of polyphenols.

4.  Test for tannins

    To 200 μl of the plant extract solution, 150 μl of 0.1% ferric chloride was added and observed for the formation of a bluish-black precipitate, which indicated the presence of tannins in the extract.

5.  Test for glycosides (Keller-Kiliani Test)

    To 200 μl of the plant extract solution, 150 μl of glacial acetic acid was added. To the resultant, a pinch of ferric chloride along with 100 μl of sulphuric acid was added. Formation of a prominent brown ring showed the presence of glycosides.

6.  Test for terpenoids (Salkowski Test)

    About 200 μl of the plant extract was mixed with 75 μl of chloroform, and 125 μl of concentrated sulphuric acid was carefully added from the sides of the test-tube to form a reddish-brown layer, which indicated the presence of terpenoids in the plant extract.

7.  Test for flavonoids

    To 200 μl of the plant extract solution, equal amount of Vanillin reagent was added. Formation of reddish-brown colour precipitate indicated the presence of flavonoids in the extract.

8.  Test for steroids (Leibermann-Burchard Test)

    To 200 μl plant extract solution, 150 μl of chloroform was added. Then 3-4 drops of acetic anhydride and three drops of concentrated sulphuric acid were added. Formation of a dark-bluish precipitate confirmed the presence of phytosterols in the extract.

9.  Test for coumarins

    To 200 μl plant sample extract solution, equal quantity of 10% sodium hydroxide solution was added and heated at 100 °C for 5 min. Formation of yellow color indicated the presence of coumarins in the plant extract.

Inhibition Assays {#s2_8}
-----------------

### Validation of HLM Assays for Efavirenz and Rifampicin {#s2_8_1}

Satisfactory separation of the drug, its metabolite and the internal standard was achieved using gradient elution ([**Figure 1**](#f1){ref-type="fig"}).

![HPLC Chromatograms showing the separation of **(A)** Efavirenz (EFV), its metabolite (E8H), and internal standard (NEO), **(B)** Rifampicin (RIF), its metabolite (25ODESRIF), and the internal standard (NEO). EFV, efavirenz; E8H, 8-Hydroxy efavirenz; NEO, neostigmine; RIF, Rifampicin; 25ODESRIF, 25-*O*-desacetyl rifampicin ([@B57]).](fphar-11-00517-g001){#f1}

Method optimization was achieved by modifying various run parameters such as change in gradient elution and, inner column diameter (2.6 and 4.6mm), length (100, 150, and 250mm), and particle size (3.5 μm and 5 μm).

A linear response was obtained in the concentration range 0--200 μM for both efavirenz and its metabolite (R^2^ = 0.9930). LLOD and LLOQ were calculated at 7.57 μM and 22.95 μM for efavirenz and 7.99 μM and 24.24 μM for 8-hydroxy efavirenz, respectively. The peak area of the internal standard neostigmine was relatively constant for all time-point incubations. For the rifampicin method, a linear response was obtained in the concentration range 0--200 μM for both rifampicin and 25-*O*-desacetyl rifampicin (R^2^ = 0.9950). LLOD and LLOQ were calculated at 5.86 μM and 17.75 μM for rifampicin and 7.78 μM and 23.57 μM for 25-*O*-desacetyl rifampicin, respectively ([**Table 1**](#T1){ref-type="table"}). Linearity was established for both time-variant HLM assays with R^2^ = 0.9918 ([@B99]; [@B55]).

###### 

HPLC method parameters for efavirenz and rifampicin.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Column                                                                          Phenomenex-Evo C-18 100A Column\   Phenomenex Luna C-18 Column (150 x 4.6 mm, 5 μm)                               
                                                                                  (150 x 4.6 mm, 2.6 μm)                                                                                            
  ------------------------------------------------------------------------------- ---------------------------------- -------------------------------------------------- ------ -------- ----------- -------
  **Drug**                                                                        EFV                                E8H                                                NEO    RIF      25ODESRIF   NEO

  **Retention Time (min)**                                                        7.57                               8.15                                               8.77   7.70     8.25        10.70

  **LLOD (μM)**                                                                   7.57                               7.99                                               --     5.86     7.78        --

  **LLOQ (μM)**                                                                   22.95                              24.24                                              --     17.75    23.57       --

  **Linear Correlation Coefficient (R^2^)**                                       0.9906                             0.9948                                             --     0.9932   0.9976      --

  **Overall Run Time (min)**                                                      10.5                               11.5                                                                           

  **HLM Time-variant assay (15-60 min): Linear Correlation Coefficient (R^2^)**   0.9934                             0.9901                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EFV, efavirenz; E8H, 8-hydroxy efavirenz; NEO, neostigmine; RIF, Rifampicin; 25ODESRIF, 25-O-desacetyl rifampicin ([@B57]).

Four incubation time points (15, 30, 45, and 60 min, in triplicates) were selected for the *in vitro* human liver microsomal incubation assays for efavirenz and rifampicin. The metabolites for both drugs were detected, separated and quantified (peak area) along with the internal standard neostigmine, at consistent retention times using the above method parameters; the peak area of neostigmine for the assays were relatively constant ([**Figure 1A, B**](#f1){ref-type="fig"}). Linearity was attained for the 15--60 min time-point incubations based on the ratio of the metabolite to the internal standard, with R^2^ = 0.9934 for efavirenz and R^2^ = 0.9901 for rifampicin, respectively ([**Figure 2**](#f2){ref-type="fig"}).

![**(A)** Standard calibration curves for pure EFV and E8H standards; **(B)** HLM time variant incubation assay linearity showing the ratio of E8H to NEO, for the specific time of incubation (15, 30, 45, and 60 min), **(C)** Standard calibration curves for pure RIF and 25ODESRIF standards **(D)**; HLM time variant incubation assay linearity showing the ratio of 25ODESRIF to NEO, for the specific time of incubation (15, 30, 45, and 60 min). EFV, efavirenz; E8H, 8-hydroxy efavirenz; NEO, neostigmine; RIF, Rifampicin; 25ODESRIF, 25-*O*-desacetyl rifampicin.](fphar-11-00517-g002){#f2}

### Kinetics of Efavirenz and Rifampicin {#s2_8_2}

The kinetics for the formation of 8-hydroxy efavirenz from efavirenz, and 25-*O*-desacetyl rifampicin from rifampicin were determined through several HLM incubations for concentrations in the range of 0--150 μM. Representative Michaelis-Menten kinetic plots from all assays were as illustrated below ([**Figure 3**](#f3){ref-type="fig"}, [**Table 2**](#T2){ref-type="table"}).

![Michaelis-Menten kinetic plots (K*~m~*) of efavirenz and rifampicin in human liver microsomes.](fphar-11-00517-g003){#f3}

###### 

Kinetics of efavirenz and rifampicin metabolism in HLM.

  ------------------------------------------------------------------------------------------------
  HLMs                                   Enzyme   SUBSTRATE   K~m~ ^\*^   V~max~   CL~int~\
                                                                                   (V~max~/K~m~)
  -------------------------------------- -------- ----------- ----------- -------- ---------------
  Pooled HLM---Mixed Gender, Xenotech\   CYP2B6   EFV         15.08       0.3576   0.0240
  (H0610, H0620, H0630, H0640)                                                     

  \                                      \        \           \           \        
  β-esterases                            RIF      48.23       1.2330      0.0260   
  ------------------------------------------------------------------------------------------------

\*V~max~, pmol/min/mg protein or pmol/min/pmol P450; K~m~, μM; CL~int~, μl/min/mg protein or μl/min/pmol P450 ([@B55]; [@B56]; [@B57]).

### IC~50~ and TDI Assays {#s2_8_3}

The inhibitory potential of each extract was assessed using two-point screening (20 and 200 μg/ml) and the activity potential was compared with the control incubates (without inhibitor). Neostigmine was used as the internal standard.

Briefly, a standard 200 μl incubation mixture containing the liver microsomes (0.5 mg/ml protein concentration for efavirenz, 0.25 mg/ml protein concentration rifampicin), efavirenz (15 μM)/rifampicin (48 μM) in 0.2M phosphate buffer (pH 7.4) and the basil herb extract (final concentration 10 or 200 μg/ml, dissolved in \<1% solvent) was incubated at 37°C for 30 min, in triplicates, with master reaction mix comprising of NADPH (final concentration 1.3 mM) and other reaction co-factors such as glucose-6-phosphate (final concentration 1.3 mM), glucose-6-phosphate dehydrogenase (1 U/ml) and magnesium chloride (final concentration 3.3 mM). About 200 μl of chilled ice-cold acetonitrile spiked with neostigmine (20 μM) was used to terminate each reaction. These samples were then centrifuged at 13,000 rpm for 10 min and the supernatants were subjected to HPLC analysis. The mobile phase comprised of water (A): acetonitrile (B) at a flow rate of 0.7 ml min^-1^ for efavirenz samples and water (A): methanol (B) at a flow rate of 0.8 ml min^-1^ for rifampicin samples. Ticlopidine and nelfinavir were used as the standard inhibitors for CYP2B6 and rifampicin metabolism pathway ([@B74]; [@B33]). The percentage of remaining activity was expressed as in the equation below (equation 2.8.3.1):
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A concentration range of 1--200 μg/ml of each active basil extract (six-point screening), in triplicates, was used to determine the IC~50~. Ticlopidine and nelfinavir were screened in within concentration ranges 1--100 μM (0--66.30 μg/ml) to determine their IC~50~ values. The percentage of remaining activity was plotted on GraphPad prism against the log-transformed concentrations of the herbal extract or the positive control, using non-linear dose-response inhibition regression analysis to obtain the sigmoidal curves for the IC~50~s.

For the TDI assays, the active basil extracts were pre-incubated with HLM and buffer (90 μl) and the co-factors (reaction master mix, 100 μl) at 37°C for 30 min prior to addition of 10 μl of the substrate (15 μM efavirenz or 48 μM rifampicin).

The TDI fold-shift was calculated using the ratio of the IC~50~s of the normal assay IC~50~(-) to that of the pre-incubation assay IC~50~(+), with NADPH (equation 2.8.3.2).
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Extracts with fold shifts ≥1.5 were classified positive for TDI ([@B69]).

The dose-response curves in sections *Preparation of Plant Extracts* and *Human Liver Microsomes and HepG2 Cell Lines* represent the IC~50~ (μM) calculated using non-linear regression (dose-response inhibition) v/s the actual IC~50~ plot curve-fit.

### Hepatic Blood Concentrations---Prediction on Inhibition Percentage {#s2_8_4}

The concentrations of each basil extract in the GIT and in hepatic blood were estimated using the percentage yield (% ^W^/~W~, section *Reagents and Chemicals*) on the basis of a basic model ([@B27]) where the maximal unbound plasma concentration of the interacting herb \[I\] was calculated using an estimated available GIT fluid of 250 ml ([@B64]; [@B94]) and the recommended single dosage of each extract obtained from various online sources (<https://www.drugs.com>; <https://draxe.com/>; <http://naturimedica.com>) and the label insert instructions obtained for the crude basil extracts obtained from Pharma Germania, Benoni (equation 2.8.4.1).

Putative GIT Conc. 

(

μ

g

/

ml

)

=

(

Recommended single dose

(

μ

g

/

ml

)

)

/

250

The available hepatic blood concentration of the extract \[I\] was calculated using the putative GIT concentration value, based on the equation (2.8.4.2).
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The inhibition constant (K~i~) for each extract was calculated based on the IC~50~ values on the assumption that most documented CYP inhibitions are competitive, as per the following equation (2.8.4.3):
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S and K~m~ values denote the substrate concentration used in this study and the affinity constant for the metabolic activity, respectively \[15\]. Likely hepatic HDI predictions for the basil extracts were assessed and evaluated based on comparison of the estimated concentration hepatic blood to the IC~50~ value for each extract and the predicted percentage of inhibition was calculated using the inhibitory concentration \[I\] as per the following equation (2.8.4.4).
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The herbs were ranked for their potential risk in causing HDI based on the inhibitory potency (\[I\]/K~i~ inhibitory ratio). According to the FDA guidelines, \[I\]/K~i~ \> 1.0 is correlated to high risk of potential DDI, \[I\]/K~i~=0.1--1 is correlated to intermediate risk for DDI and \[I\]/K~i~ \< 0.1 is unlikely to cause any significant interactions ([@B75]). This study did not use static and dynamic mechanistic models to evaluate the plasma concentration-time curve ratio (AUCR) for the target drugs in the presence of the herbal extracts, as recommended in the FDA clinical pharmacology guidelines ([@B27]).

Induction Assays {#s2_9}
----------------

### Cytotoxicity Testing and Determination of CC~50~ {#s2_9_1}

Stock solution of each basil extract was prepared in DMEM medium supplemented with 2% inactivated FBS (10% w/v concentration) and filtered using 0.22 µm syringe filter. Serial two-fold dilutions were prepared from this for carrying out the cytotoxicity studies. HepG2 cells were cultured in DMEM supplemented with 10% inactivated FBS, penicillin (100 IU/ml), streptomycin (100 μg/ml) and amphotericin B (5 μg/ml) in a humidified atmosphere (5% CO~2~) at 37°C until confluency was attained ([@B35]).

Cytotoxicity of the plant extracts was evaluated based on the method described in a previous study on *Plectranthus barbatus* Andrews ([@B66]). In brief, HepG2 cell suspension was added to 96-well microtitre plate and after 24 h, the supernatant was flicked off, the monolayer formed was washed with medium and 100 μl of each extract was added; the plates were incubated in 5% CO~2~ atmosphere at 37°C for 72 h. Post this, the solution in each well was discarded and 50 μl of tetrazolium dye (MTT) in PBS was added; plates were incubated for 3 h. Post this, 100 μl iso-propanol was added and absorbance was measured at 540 nm using plate reader. The growth inhibition percentage was calculated as per the following equation (2.9.1.1):
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The dose-response curves against cell lines were used to determine the half-cytotoxicity concentration (CC~50~) ([@B97]).

### mRNA Expression for CYP2B6 and 3A4 {#s2_9_2}

CC~50~ concentration of each extract was added to 60 mm petridish comprising of the HepG2 cells cultured in DMEM medium, FBS and amphotericin (48 h) and incubated for 24 h. Total cellular RNA was isolated from the untreated (control) and treated cells using Tri-Xtract™ as per the protocol provided by the manufacturer (G-Biosciences Ltd). cDNA was synthesized from each isolated RNA by reverse transcriptase kit (Thermo Scientific Ltd. protocol). Primers for CYP3A4 and CYP2B6 were selected as per a method developed previously for analysing the modulation of CYPs ([@B72]). 50 μl of the reaction mixture (1x cDNA synthesis buffer, dithiothreitol (0.5 M), RiboLock RNAse inhibitor (20 U), deoxynucleotide mix (1.6 mM), oligo dT (100 ng), reverse transcriptase (25 U), and total RNA) was subjected to PCR for amplification of hepatic cells. cDNAs using specifically designed primers (procured from Eurofins, India) were used. The house keeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was co-amplified with each reaction as internal control. Rifampicin (50 μM) and dexamethasone (10 μM) were used as positive controls for CYP3A4 and CYP2B6, respectively ([@B66]). For CYP3A4 oligo dT primer was used for first strand synthesis and for second strand synthesis, 5′ ATTCAGCAAGAAGAACAAGGACA 3′ and 5′ TGGTGTTCTCAGGCACAGAT 3′ were used as the forward and reverse primers, respectively. For 2B6, oligo dT primer was used for first strand synthesis and for second strand synthesis, 5′ ATGGGGCACTGAAAAAGACTGA 3′ and 5′ AGAGGCGGGGACACTGAATGAC 3′ were used as the forward and reverse primers, respectively.

The amplified samples were further analyzed using agarose gel electrophoresis. The gel was further developed using UV illumination-digital imaging, and Syngene inGenius documentation system and GeneTools analysis software was used for calculating the expression levels per sample; one-way analysis of variance, followed by Dunnett's multiple comparison tests, by fixing the significance level at p \< 0.05, p \< 0.01 and p \< 0.001 was used ([@B66]).

LC-MS Conditions: Phyto-Profiling {#s2_10}
---------------------------------

Stock solutions were prepared by adding 8-10 mg of each extract to 1 ml of 50% methanol in water containing 2% formic acid, followed by dissolution in an ultrasonic bath (0.5 Hz, Integral Systems, RSA) for 20 min at room temperature. The extracts were then centrifuged and supernatants were analyzed for phytocomposition. The reference standards quercetin and gallic acid ([@B98]; [@B80]) were prepared in cocktail stock solutions with concentration of 200 mg/L of each standard. 2 μl of each extract was injected into the LC-MS prepped with a mobile phase comprising of 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid as solvent B. A flow rate of 0.3 ml min^−1^, was maintained for gradient elution starting with 100% solvent A for 1 min, which was linearly changed to 28% B over 22 min, then changed to 40% B over 50 seconds followed by a 1.5 min wash step with 100% solvent B, and finally re-equilibration (to initial conditions) for 4 min. The column temperature was maintained at 55°C. The PDA wavelength range was set between 230 and 600 nm.

The methods were tested for accuracy and linearity. A linear response was obtained for quercetin for the positive mode run, in the range of 200.000--6.250 mg/l (R^2^ = 0.9900) ([**Figure 4**](#f4){ref-type="fig"}). This concentration range was selected to identify and compare the peak-retention factors and *m/z* of the extract with the reference standard, along with reasonable approximations of the relative amounts of the identified peaks using the standard calibration curve of quercetin. The calibration curve showed slight non-linearity at higher concentrations (200 mg/l) for both standards in the negative mode. A quadratic linear curve fitting model was used for quercetin (R^2^ = 0.9879) for relative quantification of the unknown phytocompounds, based on the peak area (response) for the concentration range used (200.000--6.250 mg/L) whereas a linear fit model was used for gallic acid (R^2^ = 0.9680) since the peak area (response) was less for low concentrations.

![**(A)** Concentration range linearity for quercetin (R^2^ = 0.9879) in positive mode LC-MS scan, **(B, C)**---regression line-fit concentration range linearity for gallic acid & quercetin (R^2^ = 0.9441 & 0.9678) in LC-MS negative mode scans, respectively.](fphar-11-00517-g004){#f4}

Tentative identification of the phytocompounds was done based on the following parameters ([@B90]):

-   Accurate masses

-   *m/z* transitions (MS/MS fragments)

-   UV maxima

-   Relative retention times and comparison with literature review on matching compounds

Online mass spectral repositories such as Metlin Scripps (<https://metlin.scripps.edu/>), MassBank online Spectral Database (<https://massbank.eu/MassBank/>), NIST standard reference data online webbook library (<http://webbook.nist.gov/chemistry/mw-ser.html>), and Pubchem chemistry database (<https://pubchem.ncbi.nlm.nih.gov>).

Results {#s3}
=======

Extraction and Yield of Basil Extracts for Bioassays {#s3_1}
----------------------------------------------------

Exhaustive extraction of basil herb was done with water, methanol, ethanol and ethyl acetate; per 4g of the dried basil extract, highest solvent yield was observed in the aqueous extract (Basil~Aq~) of basil with 33.57%, followed by the methanol solvent (Basil~MeOH~) at 9.44% and ethyl acetate (Basil~EtOAc~) at 4.93%. Ethanol extract (Basil~EtOH~) yield was the least with 2.94% ([**Table 3**](#T3){ref-type="table"}).

###### 

Extraction yield of basil extracts.

  Yield (^±^ mg, % ^W^/~W~)                                           
  --------------------------- ------------------- ------------------- -------------------
  ^±^ 1343 mg, 33.57%         ^±^ 378 mg, 9.44%   ^±^ 118 mg, 2.94%   ^±^ 193 mg, 4.83%

^±^mg - approximate, negating the residual amount of extract retained in the glass tubes after scraping.

Biochemical Phytoprofiling {#s3_2}
--------------------------

The biochemical qualitative tests confirmed the presence of phytoconstituents such as alkaloids, glycosides, terpenoids, phenols, coumarins and flavonoids within the extracts; precipitate formation and color intensity formed the basis for the chemical tests ([**Table 4**](#T4){ref-type="table"}). All four basil extracts showed positive to the detection tests for all compounds, coumarins and phytosteroids present in trace amounts.

###### 

Biochemical qualitative profile of basil extracts.

  ----------------------------------------------------------------------------------------------------------------------------------------
  Sl \#          Phyto Constituent   Test                                   Reference                              Extract     Inference
  -------------- ------------------- -------------------------------------- -------------------------------------- ----------- -----------
  1 a.           Alkaloids           Harborne Test                          *Biochemical Phyto-Profiling*---1, a   Basil~Aq~   ✓ ++

  Basil~MeOH~    ✓ +++                                                                                                         

  Basil~EtOH~    ✓ ++                                                                                                          

  Basil~EtOAc~   ✓ ++                                                                                                          

  1 b.           Wagner's Test       *Biochemical Phyto-Profiling*---1, b   Basil~Aq~                              ✓ +++       

  Basil~MeOH~    ✓ +++                                                                                                         

  Basil~EtOH~    ✓ +++                                                                                                         

  Basil~EtOAc~   ✓ +                                                                                                           

  2              Saponins            Emulsion test                          *Biochemical Phyto-Profiling*---2      Basil~Aq~   ✓ +++

  Basil~MeOH~    ✓ +++                                                                                                         

  Basil~EtOH~    ✓ +++                                                                                                         

  Basil~EtOAc~   ✓ ++                                                                                                          

  3              Phenols             Ferric Chloride Test                   *Biochemical Phyto-Profiling*---3      Basil~Aq~   ✓ +++

  Basil~MeOH~    ✓ +++                                                                                                         

  Basil~EtOH~    ✓                                                                                                             

  Basil~EtOAc~   ✓                                                                                                             

  4              Tannins             Harborne Test                          *Biochemical Phyto-Profiling*---4      Basil~Aq~   ✓ +++

  Basil~MeOH~    ✓ +++                                                                                                         

  Basil~EtOH~    ✓ +                                                                                                           

  Basil~EtOAc~   ✓                                                                                                             

  5              Glycosides          Keller-Kiliani Test                    *Biochemical Phyto-Profiling*---5      Basil~Aq~   ✓

  Basil~MeOH~    ✓ +++                                                                                                         

  Basil~EtOH~    ✓ +++                                                                                                         

  Basil~EtOAc~   ✓                                                                                                             

  6              Terpenoids          Salkowski Test                         *Biochemical Phyto-Profiling*---6      Basil~Aq~   ✓ +++

  Basil~MeOH~    ✓ +++                                                                                                         

  Basil~EtOH~    ✓ +++                                                                                                         

  Basil~EtOAc~   ✓ +                                                                                                           

  7              Flavonoids          Vanillin Test                          *Biochemical Phyto-Profiling*---7      Basil~Aq~   ---

  Basil~MeOH~    ✓ +++                                                                                                         

  Basil~EtOH~    ✓ +++                                                                                                         

  Basil~EtOAc~   ✓ +                                                                                                           

  8              Steroids\           Liebermann-Burchard Test               *Biochemical Phyto-Profiling*---8.     Basil~Aq~   ---
                 (phytosterols)                                                                                                

  Basil~MeOH~    ---                                                                                                           

  Basil~EtOH~    ✓                                                                                                             

  Basil~EtOAc~   ✓                                                                                                             

  9              Coumarins           Sodium Hydroxide Test                  *Biochemical Phyto-Profiling*---9      Basil~Aq~   ✓

  Basil~MeOH~    ---                                                                                                           

  Basil~EtOH~    ---                                                                                                           

  Basil~EtOAc~   ✓                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------

**✓** Present, ++ colour intensity of precipitate/reaction, ---Absent

HLM Screening and IC~50~ Assays {#s3_3}
-------------------------------

HLM assays were used to evaluate the inhibitory effect of basil extracts on CYP2B6 and rifampicin metabolism. The aqueous and methanolic extracts reduced CYP2B6 activity by less than 50% at 200 μg/ml concentrations, whereas the positive control ticlopidine reduced the activity to 50% at 19.78 μg/ml. For the two-point screening against rifampicin metabolism, except for the aqueous extract, all extracts inhibited the formation of 25-*O*-desacetyl rifampicin; ethanol extract reduced the activity to less than 40%. The positive control nelfinavir reduced the activity by 30% at 49.79 μg/ml concentrations ([**Figure 5**](#f5){ref-type="fig"}).

![2-Point screening of all basil extracts against CYP2B6 (efavirenz) and rifampicin metabolism; TICL (ticlopidine) and NELF (nelfinavir) are the positive controls.](fphar-11-00517-g005){#f5}

For CYP2B6 IC~50~ screening of the extracts, the methanolic extract inhibited the efavirenz metabolism pathway with an IC~50~ value 36.07 μg/ml, while the aqueous extract had an IC~50~ value of 54.96 μg/ml ([**Figures 6A--C**](#f6){ref-type="fig"}). The positive control ticlopidine had an IC~50~ of 14.47 μg/ml (54.88 μM) when tested for inhibition activity, in a concentration range of 0--26.38 μg/ml (0--100 μM).

![Dose-response curves of basil extracts (with IC~50~s) for **(A)** aqueous extract (54.96 μg/ml), **(B)** methanolic extract (36.07 μg/ml), and positive control **(C)** ticlopidine (14.47 μg/ml, 54.88 μM) against percentage remaining activity of CYP2B6 with efavirenz as the substrate. Figures **(D)** methanolic extract (31 μg/ml), **(E)** ethanolic extract (8.94 μg/ml), and positive control **(F)** nelfinavir (5.44 μg/ml, 9.59 μM) represent the IC~50~ dose-response curves of basil extracts against percentage remaining activity of rifampicin metabolism. The IC~50~ is calculated as log(X) against Y.](fphar-11-00517-g006){#f6}

The ethanolic extract inhibited the rifampicin metabolism pathway, with the lowest IC~50~ value 8.94 μg/ml, while the methanolic extract exhibited an IC~50~ value of 31 μg/ml. The positive control nelfinavir inhibited the formation of 25-*O*-desacetyl rifampicin with an IC~50~ value of 5.44 μg/ml ([**Figures 6D--F**](#f6){ref-type="fig"}).

TDI IC~50~ Fold Shift Determination {#s3_4}
-----------------------------------

Time-dependent inhibition (TDI) is the irreversible inhibition of the enzyme activity, where the potency of the inhibitor increases on prolonged exposure to the CYPs during pre-incubation time period. For basil extracts the TDI was assessed by pre-incubation with NADPH for 30 min ([@B91]). The aqueous and methanolic extracts exhibited TDI of CYP2B6 activity with IC~50~ values 33.35 and 4.93 μg/ml, respectively. However, none of the extracts demonstrated TDI effects against the rifampicin metabolism pathway; for the ethanolic extract, the IC~50~ shift observed was \> 100 μg/ml. Comparatively both positive controls showed clear TDI with IC~50~ shifts to 9.63 μg/ml for ticlopidine against CYP2B6, and 3.63 μg/ml for nelfinavir against rifampicin pathway ([**Figure 7**](#f7){ref-type="fig"}).

![Dose-response curves of basil extracts (with TDI IC~50~s) for **(A)** aqueous extract (33.35 μg/ml), **(B)** methanolic extract (4.93 μg/ml), and positive control **(E)** ticlopidine (9.63 μg/ml, 36.51 μM) against percentage remaining activity of CYP2B6 (efavirenz as substrate) and **(C)** methanolic extract (\> 100 μg/ml), **(D)** ethanolic extract (75.76 μg/ml) and, **(F)** positive control nelfinavir (3.63 μg/ml, 6.39 μM) against percentage remaining activity of rifampicin metabolism. The TDI IC~50~ is calculated as log(X) against Y. The plot demonstrates the TDI IC~50~ (μM) calculated using non-linear regression (dose-response inhibition) v/s the actual IC~50~ plot curve-fit.](fphar-11-00517-g007){#f7}

The IC~50~ shift-fold was calculated as the ratio of the co-incubation IC~50~(-) to the pre-incubation IC~50~(+) with NADPH, for each extract and the controls. The aqueous and methanolic extracts showed positive TDI for CYP2B6; the methanolic extract exhibited strong TDI with 7.4-fold increase in the IC~50~. Both positive controls ticlopidine and nelfinavir demonstrated clear TDI with the IC~50~ shift-fold \>1.5 ([**Figure 8**](#f8){ref-type="fig"}).

![TDI Shift-fold plots. Bars represent the ratio of co-incubation IC~50~(-) values for the extracts to the pre-incubation IC~50~(+) values with NADPH, for basil extracts. Ticlopidine (TICL) and nelfinavir (NELF) were positive controls for CYP2B6 and rifampicin pathway, respectively.](fphar-11-00517-g008){#f8}

HEPG2 Induction Assays {#s3_5}
----------------------

For the MTT assays, all basil extracts were screened for *in vitro* cytotoxicity levels against HepG2 cells, by exposing the cells to various concentrations of each extract (1,000.00--31.25 μg/ml). The concentration of the test extract needed to inhibit cell growth by 50%--CC~50~ values were calculated for the four basil extracts as illustrated in [**Table 5**](#T5){ref-type="table"}. The ethanolic extract had the lowest CC~50~ of 70.58 ± 0.83 μg/ml in HepG2 cells ([**Table 5**](#T5){ref-type="table"}).

###### 

Concentration of each basil extract that causes 50% cytotoxicity in HepG2 cells (CC~50~).

  ------------------------------------------------------------------------------
  Sample Name    Concentration (µg/ml)   Cytotoxicity (%)   CC~50~ (µg/ml)^\#^
  -------------- ----------------------- ------------------ --------------------
  Basil~Aq~      1,000\                  66.95 ± 1.35\      205.73 ± 1.26
                 500\                    61.34 ± 1.73\      
                 250\                    53.85 ± 0.54\      
                 125\                    42.98 ± 0.94\      
                 62.5                    2.23 ± 0.33        

  Basil~MeOH~    1,000\                  72.20 ± 1.17\      216.30 ± 3.35
                 500\                    58.80 ± 0.78\      
                 250\                    54.50 ± 0.72\      
                 125\                    37.90 ± 0.52\      
                 62.5                    14.10 ± 1.05       

  Basil~EtOH~    1,000\                  90.75 ± 0.15\      70.58 ± 0.83
                 500\                    89.13 ± 0.67\      
                 250\                    75.38 ± 0.54\      
                 125\                    65.08 ± 0.33\      
                 62.5                    47.75 ± 0.31       

  Basil~EtOAc~   1,000\                  97.43 ± 0.15\      320.18 ± 2.13
                 500\                    61.92 ± 1.67\      
                 250\                    40.53 ± 2.54\      
                 125\                    25.77 ± 0.33\      
                 62.5                    7.86 ± 0.31        
  ------------------------------------------------------------------------------

^\#^Values are represented as mean ± SD (n = 3). CC~50~ calculated as the mean ± SD of cytotoxicity % values on HepG2 cells at concentration range 1000--31.25 µg/ml for each extract.

Based on the CC~50~ values, the inducing effect of each extract on mRNA expression of the HepG2 cells was determined using RT-PCR and AGE techniques. The expression levels of CYP2B6 and CYP3A4 are depicted as arbitrary units normalized to (GAPDH) mRNA ([**Figure 9**](#f9){ref-type="fig"}).

![Relative CYP3A4 and CYP2B6 mRNA expressions by CC, rifampicin, dexamethasone and basil extracts on agarose gel; relative expression of GAPDH mRNA on agarose gel for normalization.](fphar-11-00517-g009){#f9}

For CYP3A4, the positive control rifampicin (50 μM) showed significant fold induction (p \< 0.001) compared to the cell control (CC). None of the extracts showed 2-fold induction on CYP3A4 mRNA expression indicating that they were only moderate inducers. All basil extracts induced CYP3A4, with the methanolic extract showing 22%-fold response increase and ethanolic extract at 44%. However, none of the extracts induced both CYPs over 2-fold, indicating that the phytomolecules present in these extracts are not strong inducers of CYP2B6 and 3A4. Based on the results observed in the mRNA expression assays in HepG2 cells, it was concluded that CYP3A4 was more inducible by basil extracts compared to CYP2B6 ([**Figure 10A**](#f10){ref-type="fig"}).

![Graphs of the herbal extracts and their fold responses for CYP3A4 and 2B6 mRNA expression, relative to cell control (CC); rifampicin (RIF) and dexamethasone (DEX) as positive controls, **(A, B)** respectively.](fphar-11-00517-g010){#f10}

Dexamethasone (10 μM), the positive control against CYP2B6, showed significant fold induction (p \< 0.001) when compared to the cell control (CC, no inducer). In comparison, the extracts showed less than 2-fold induction and therefore were only moderate inducers. The methanolic and ethanolic extracts moderately induced CYP2B6 mRNA with 38%- and 28%-fold shifts respectively ([**Figure 10B**](#f10){ref-type="fig"}).

Fingerprint Analysis of the Phytoconstituents {#s3_6}
---------------------------------------------

The identified phytocompounds (acidic and non-acidic compounds) were relatively quantified using gallic acid and quercetin as reference standards. Gallic acid calibration was determined in negative scan mode in the MS since most of the acidic compounds were detected in the same scan mode. Each negative scan was performed for 29 min, whereas the positive scan spanned 15 min ([**Figures 11A, B**](#f11){ref-type="fig"}).

![**(A)** LC-MS chromatogram of basil extracts in negative mode scan for time duration of 29 min. **(B)** LC-MS chromatogram of basil (ethanol extract) in negative mode scan for time duration of 29 min, LC-MS spectra focusing on rosmarinic acid \[*m/z* 359.0764 (M-H)^-^\].](fphar-11-00517-g011){#f11}

In the negative scan mode, the major observations noted for the extracts are as follows (for details, see [**Table 6**](#T6){ref-type="table"}):

###### 

Compounds detected in *O.basilicum* extracts in negative scan mode in LC-MS/PDA.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  SL\           RT (min)   M-H        \[M-H\]^--^       MS/MS*^c^*                     Tentative ID^\#^                                  Type of Compound
  No.                                                                                                                                    
  ------------- ---------- ---------- ----------------- ------------------------------ ------------------------------------------------- -------------------------
  Basil~Aq~                                                                                                                              

  1             21.65      359.0764   C~18~H~15~O~8~    161, 133, 135, 179, 197        Rosmarinic acid                                   Phenolic acid

  2             1.75       149.0076   C~4~H~5~O~6~      113, 130.997, 141              Tartaric acid                                     Organic acid

  3             3.86       191.0175   C~6~H~7~O~7~      111, 129, 173                  Isocitric acid                                    Citric acid

  4             24.36      327.2150   C~18~H~15~O~6~    116.9, 205, 215, 277, 311      Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone)   Flavones

  5             10.59      311.0392   C~13~H~11~O~9~    135, 149, 179, 311             Caftaric acid\                                    Non-flavanoid phenolic
                                                                                       (Caffeoyl-tartaric acid)                          

  8             16.22      225.1110   C~12~H~17~O~4~    112, 135, 161, 192, 203, 216   12-hydroxyjasmonic acid                           Carboxylic acid

  6             18.23      473.0708   C~22~H~17~O~12~   135, 149, 179, 293, 311        Chicoric acid\                                    Hydroxycinnamic acid
                                                                                       (dicaffeoyl-tartaric acid)                        

  7             23.38      717.1448   C~36~H~29~O~16~   243, 343, 519                  Unknown                                           --

  Basil~MeOH~                                                                                                                            

  1             21.61      359.0764   C~18~H~15~O~8~    161, 133, 135, 179, 197        Rosmarinic acid                                   Phenolic acid

  2             1.79       341.1076   C~12~H~21~O~11~   89, 173                        Dihexose                                          Sugar

  3             24.36      327.2150   C~18~H~15~O~6~    116.9, 205, 215, 277, 311      Salvigenin\                                       Flavones
                                                                                       (5-Hydroxy-6,7,4′-trimethoxyflavone)              

  4             18.09      609.1499   C~27~H~29~O~16~   151, 255, 271, 300, 301        Rutin\                                            Flavonoid
                                                                                       (Quercetin-hexoside-rhamnoside)                   

  5             14.45      387.1648   C~21~H~23~O~7~    59, 119, 207, 300              Medioresinol                                      Furanoid lignin

  6             18.74      463.0882   C~21~H~19~O~12~   89, 151, 255, 271, 300         Isoquercetin (Quercetin-hexoside)                 Flavonoid

  7             23.38      717.1450   C~36~H~29~O~16~   243, 343, 519                  Unknown                                           --

  8             20.99      137.1212   C~9~H~13~O        93, 121                        trans-ocimene oxide                               Monoterpenes

  Basil~EtOH~                                                                                                                            

  1             21.6       359.0764   C~18~H~15~O~8~    161, 133, 135, 179, 197        Rosmarinic acid                                   Phenolic acid

  2             9.35       153.4201   C~10~H~17~O       79, 93, 109, 127, 137          Linalool\                                         Terpene alcohol
                                                                                       (2,6-Dimethyl-2,7-octadien-6-ol; allo-Ocimenol)   

  3             24.36      327.2150   C~18~H~15~O~6~    116.9, 205, 215, 277, 311      Salvigenin\                                       Flavone
                                                                                       (5-Hydroxy-6,7,4′-trimethoxyflavone)              

  4             14.76      431.1907   C~21~H~19~O~10~   153, 205, 269, 354, 385        Apigenin-7-O-glucoside                            Flavonoid glycoside

  5             13.82      179.0330   C~9~H~7~O~4~      135                            Caffeic acid                                      Hydroxycinnamic acid

  6             24.43      329.2310   C~18~H~33~O~5~    171, 211                       Trihydroxy octadecenoic acid                      Fatty acid

  7             21.15      187.0944   C~9~H~15~O~4~     125, 158, 169                  Eucommiol                                         Cyclopentene dimethanol

  8             16.19      225.1113   C~12~H~17~O~4~    112, 135, 161, 192, 203, 216   12-hydroxyjasmonic acid                           Carboxylic acid

  9             18.71      463.0874   C~21~H~19~O~12~   89, 151, 255, 271, 300         Isoquercetin\                                     Flavonoid
                                                                                       (Quercetin-hexoside)                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

^\#^References -- [@B44]; [@B63]; [@B86]; [@B13]; [@B90]; [@B82]; <https://www.ncbi.nlm.nih.gov/pccompound>; <https://massbank.eu/MassBank/>; <https://metlin.scripps.edu/>; <https://webbook.nist.gov/chemistry/mw-ser/>.

1.  Rosmarinic acid, a polyphenol was the most prominent peak in all extracts of basil ([**Figure 12A**](#f12){ref-type="fig"}). It had a retention time of 21.65 min at *m/z* 359 (M-H)^-^ and detection wavelength of 329nm on the PDA ([**Figure 12A**](#f12){ref-type="fig"}). The product ions were identified at *m/z* 161, 133, 135, 179, and 197 ([**Figure 11B**](#f11){ref-type="fig"}).

2.  The flavone salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone) was prominentlyobserved in the extracts, at retention time 24.36 min and *m/z* 327(M-H)^-^, with product ions at *m/z* 116.9, 205, 215, 277 and 311 ([**Figure 12B**](#f12){ref-type="fig"}).

3.  Acidic compounds such as tartaric, isocitric, caftaric and chicoric acids were prominently observed in the aqueous extract at *m/z* 149, 191, 311, and 473, at wavelengths 230 nm for the first two and 328--329 nm for the latter two compounds ([**Figures 12C--E**](#f12){ref-type="fig"}).

4.  Rutin, a major flavonoid, was observed only in the methanolic extract at *m/z* 609 (M-H)^-^ with products ions at *m/z* 151, 255, 271, 300 and 301 ([**Figure 12F**](#f12){ref-type="fig"}).

5.  Apigenin-7-O-glucoside or apigetrin (also known as cosmosiin), a flavonoid-7-O-glycoside, was detected in the ethanolic extract with a retention time 14.76 min and *m/z* 431 (M-H)^-^.

6.  Other significant compounds detected in the extracts were eucommiol \[*m/z* 187 (M-H)^-^\], 12-hydroxyjasmonic acid \[*m/z* 225 (M-H)^-^\], trans-ocimene oxide \[*m/z* 137 (M-H)^-^\], and medioresinol \[*m/z* 387 (M-H)^-^\].

![Chemical structures of the main compounds identified from crude herbal extracts of *O.basilicum*: **(A)** Rosmarinic acid; **(B)** Salvigenin; **(C)** Tartaric acid; **(D)** Isocitric acid; **(E)** Caftaric acid; **(F)** Rutin; **(G)** Eupatorin; and **(H)** 2,6-Pyridinedicarboxylic acid, nonyl phenethyl ester.](fphar-11-00517-g012){#f12}

In the positive mode MS scans ([**Figure 11B**](#f11){ref-type="fig"}), the major phytocompounds detected ([**Table 7**](#T7){ref-type="table"}) in the extracts included:

1.  Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone)---the most prominent peak in the methanol and ethanolic extracts, with a retention time of 7.32 min at *m/z* 329 (M+H)^+^ and PDA detection wavelength 230 nm ([**Figure 12B**](#f12){ref-type="fig"}).

2.  2,6-Pyridinedicarboxylic acid, nonyl phenethyl ester \[at *m/z* 398 (M+H)^+^\] was detected in all the extracts with product ions *m/z* 149, 240, and 266 ([**Figure 12H**](#f12){ref-type="fig"}).

3.  The flavone eupatorin \[3′,5-dihydroxy-4′,6,7-trimethoxyflavone, *m/z* 345 (M+H)^+^\] ([**Figure 12G**](#f12){ref-type="fig"}) and the aromatic lactone furan-2(3*H*)-one complex \[*m/z* 311 (M+H)^+^\] were the other major compounds identified, at retention times 6.42 and 6.91 min, respectively.

###### 

Secondary metabolites/compounds detected in *O.basilicum* extracts in positive scan mode in LC-MS/PDA.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SL\           RT (min)   M+H        \[M+H\]^+^                        MS/MS*^c^*               Tentative ID^\#^                                       Type of compound
  No.                                                                                                                                                   
  ------------- ---------- ---------- --------------------------------- ------------------------ ------------------------------------------------------ -----------------------
  Basil~Aq~                                                                                                                                             

  1             10.63      398.2331   C~24~H~32~NO~4~                   149, 240, 266            2,6-Pyridinedicarboxylic acid, nonyl phenethyl ester   Carboxylic acid

  2             7.74       304.3008   C~21~H~38~N                       91, 212                  Pyridine/Amine complex                                 Secondary Metabolites

  3             12.28      411.2662   C~30~H~35~O                       175, 283, 355            Unknown                                                --

  4             6.91       311.2210   C~18~H~31~O~4~                    96, 149, 219, 275        Furan-2(3*H*)-one complex                              Aromatic lactone

  5             9.06       399.2498   C~25~H~35~O~4~, C~18~H~39~O~9~    221, 324                 Unknown                                                --

  Basil~MeOH~                                                                                                                                           

  1             7.32       329.1014   C~18~H~17~O~6~                    133, 268                 Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone)        Flavones

  2             10.63      398.2324   C~24~H~32~NO~4~                   149, 240, 266            2,6-Pyridinedicarboxylic acid, nonyl phenethyl ester   Carboxylic acid

  3             7.74       304.2997   C~21~H~38~N                       91, 212                  Pyridine/Amine complex                                 Secondary Metabolites

  4             6.42       345.0979   C~18~H~17~O~7~                    182, 240, 312, 315       Eupatorin (3′,5-Dihydroxy-4′,6,7-trimethoxyflavone)    Flavones

  Basil~EtOH~                                                                                                                                           

  1             7.32       329.1023   C~18~H~17~O~6~                    133, 268                 Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone)        Flavones

  2             6.42       345.0959   C~18~H~17~O~7~                    182, 240, 312, 315       Eupatorin (3′,5-Dihydroxy-4′,6,7-trimethoxyflavone)    Flavones

  3             7.16       445.2117   C~21~H~33~O~10~, C~32~H~29~O~2~   105, 194 224, 385, 407   Unknown                                                --

  4             10.63      398.2336   C~24~H~32~NO~4~                   149, 240, 266            2,6-Pyridinedicarboxylic acid, nonyl phenethyl ester   Carboxylic acid
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^\#^References -- [@B104]; [@B44]; [@B12]; [@B101]; <https://www.ncbi.nlm.nih.gov/pccompound>; <https://massbank.eu/MassBank/>; <https://metlin.scripps.edu/>; <https://webbook.nist.gov/chemistry/mw-ser/>.

The identified compounds were quantified (in mg/L equivalent units of gallic acid/quercetin) relative to the linear calibration curve of the reference standards ([**Table 8**](#T8){ref-type="table"}).

###### 

Concentration of each compounds identified within the basil extracts (mg/L equivalents).

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  \# SL No        Compound Name                                         Sample name   Area        RT(min)   Conc. units \*\
                                                                                                            (mg/L equivalents of gallic acid/quercetin)
  --------------- ----------------------------------------------------- ------------- ----------- --------- ---------------------------------------------
  Compound (1)    Rosmarinic acid                                                                           \*\*

  1                                                                     Basil~Aq~     1699.1760   21.61     2298.037

  2                                                                     Basil~MeOH~   1423.3300   21.61     1923.756

  3                                                                     Basil~EtOH~   585.0240    21.61     786.304

  Compound (2)    Tartaric acid                                                                             

  1                                                                     Basil~Aq~     593.9001    1.76      798.347

  2                                                                     Basil~MeOH~   33.9320     1.76      38.556

  3                                                                     Basil~EtOH~   45.3010     1.76      53.982

  Compound (3)    Isocitric acid                                                                            

  1                                                                     Basil~Aq~     742.4790    3.88      999.946

  Compound (4)    Caftaric acid                                                                             

  1                                                                     Basil~Aq~     407.1970    10.60     545.019

  Compound (5)    Chicoric acid                                                                             

  1                                                                     Basil~Aq~     371.2370    18.23     496.228

  2                                                                     Basil~MeOH~   22.3180     18.26     22.798

  Compound (6)    Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone)                                           \*\*\*

  1                                                                     Basil~Aq~     430.9610    24.36     73.634

  2                                                                     Basil~MeOH~   213.4770    24.36     24.150

  3                                                                     Basil~EtOH~   670.6350    24.36     128.167

  Compound (7)    Rutin (Quercetin-Hexoside-rhamnoside)                                                     

  1                                                                     Basil~Aq~     80.0950     18.07     0.010

  2                                                                     Basil~MeOH~   144.1280    18.09     8.371

  3                                                                     Basil~EtOH~   146.4550    18.07     8.900

  Compound (8)    Isoquercetin (Quercetin-Hexoside)                                                         

  1                                                                     Basil~MeOH~   108.5580    18.73     0.277

  2                                                                     Basil~EtOH~   156.3420    18.72     11.150

  Compound (9)    Linalool (2,6-Dimethyl-2,7-octadien-6-ol)                                                 

  1                                                                     Basil~EtOH~   133.6801    9.35      5.993

  Compound (10)   12-hydroxyjasmonic acid                                                                   

  1                                                                     Basil~Aq~     262.7230    16.21     348.991

  2                                                                     Basil~EtOH~   255.5850    16.19     339.305

  Compound (11)   Caffeic acid                                                                              

  1                                                                     Basil~MeOH~   29.9890     13.83     33.206

  2                                                                     Basil~EtOH~   433.6770    13.80     580.949

  Compound (12)   (E)-Fukugetin                                                                             

  1                                                                     Basil~EtOH~   45.8240     26.32     0.005

  Compound (13)   Medioresinol                                                                              

  1                                                                     Basil~MeOH~   114.7220    14.45     6.020

  2                                                                     Basil~EtOH~   69.9301     14.44     0.005

  Compound (14)   Apigenin-7-O-glucoside                                                                    

  1                                                                     Basil~MeOH~   75.4170     14.77     0.010

  2                                                                     Basil~EtOH~   404.7730    14.75     67.675

  Compound (15)   Trihydroxy octadecenoic acid                                                              

  1                                                                     Basil~Aq~     127.4110    24.44     165.393

  2                                                                     Basil~MeOH~   100.3910    24.44     128.731

  3                                                                     Basil~EtOH~   396.4770    24.44     530.474

  Compound (16)   Eucommiol                                                                                 

  1                                                                     Basil~Aq~     138.4490    21.16     7.078

  2                                                                     Basil~EtOH~   354.5340    21.15     56.244

  Compound (17)   Dihexose                                                                                  

  1                                                                     Basil~MeOH~   279.5990    1.8       39.194

  Compound (18)   Eupatorin (3′,5-Dihydroxy-4′,6,7-trimethoxyflavone)                                       

  1                                                                     Basil~Aq~     44.5180     6.42      22.874

  2                                                                     Basil~MeOH~   217.4830    6.42      111.503

  3                                                                     Basil~EtOH~   1305.0280   6.42      668.772

  Compound (19)   Salvigenin (5-Hydroxy-6,7,4′-trimethoxyflavone)                                           

  1                                                                     Basil~Aq~     75.5380     7.33      38.769

  2                                                                     Basil~MeOH~   655.0720    7.32      335.728

  3                                                                     Basil~EtOH~   3619.8580   7.32      1854.916
  -------------------------------------------------------------------------------------------------------------------------------------------------------

\*The relatively quantified concentrations are reasonable approximations of the relative amounts of the identified compounds present in each ([@B7]; [@B76]) **\*\***All the acid compounds are relatively quantified equivalent to the linear curve of gallic acid, **\*\*\***All the non- acid compounds are relatively quantified equivalent to the linear curve of quercetin.

Salvigenin concentration was highest in the ethanolic extract (1854.916 mg/L), followed by the fatty acid trihydroxy octadecenoic acid (530.474 mg/L), the flavone eupatorin (668.772 mg/L) and caffeic acid (580.949 mg/L). Rosmarinic acid was predominantly present in the aqueous extract (2298.037 mg/L), along with isocitric (999.946 mg/L), tartaric acid (798.347 mg/L), chicoric (496.228 mg/L), and caftaric acids (545.019 mg/L).

Estimated Hepatic Blood Concentration of the Extracts {#s3_7}
-----------------------------------------------------

The putative GIT concentration for the aqueous, methanolic and ethanolic extracts was 2,400 μg/ml (refer section *IC~50~ and TDI Assays* for formula). For a single recommended dose of 600 mg of basil extract, the available hepatic blood concentration \[I\] was estimated at 805.68 μg/ml for the aqueous extract against CYP2B6, 226.56 μg/ml for the methanolic extract against CYP2B6 and rifampicin metabolism, and 70.56 μg/ml for the ethanolic extract against rifampicin pathway ([**Table 9**](#T9){ref-type="table"}). The inhibitory potency \[I\]/K~i~ was \>1.0 for all the extracts exhibiting their likely potential of causing HDI. The predicted *in vivo* inhibition percentiles were at 96.70% for the aqueous extract, 94.04% for the ethanolic extract and 92.62--93.60% for the methanolic extract. However other factors such as AUC ratio of the drugs, first order absorption rate K~a~, fraction of systemic clearance of the substrate F~m~, elimination rate, CL~int~ intrinsic clearance, and the fraction absorbed after oral administration F~a~ have not been considered in this prediction model ([@B27]).

###### 

Predicted values of inhibition percentage of each extract and estimated hepatic concentration.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CYP/RIF   Extract       \% Yield   Herbal dosage\   Putative GIT Conc.\   Estimated Hep. Blood Conc.\   IC~50~\   K~i~ = IC~50~/2   Inhibitory Potency\   Risk of\   Predicted % Inhibition\
                                     (mg)             (μg/ml)               \[I\]\                        (μg/ml)                     \[I\]/Ki              HDI \*     (\[I\]/(\[I\]+K~i~)) \*100
                                                                            (μg/ml)                                                                                    
  --------- ------------- ---------- ---------------- --------------------- ----------------------------- --------- ----------------- --------------------- ---------- ----------------------------
  2B6       Basil~Aq~     33.57      600              2400                  805.68                        54.96     27.48             29.32                 Likely     96.70

            Basil~MeOH~   9.44       600              2400                  226.56                        36.07     18.04             12.56                 Likely     92.62

  RIF       Basil~MeOH~   9.44       600              2400                  226.56                        31.00     15.50             14.62                 Likely     93.60

            Basil~EtOH~   2.94       600              2400                  70.56                         8.94      4.47              15.79                 Likely     94.04
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HDI, herb-drug interaction; K~i~, inhibition constant; RIF, rifampicin; \* When these herbal extracts are co-administered with other drugs, the likelihood of a clinically relevant interaction with CYP2B6 and rifampicin metabolism, was based on the assumption that the % yield serves as the bioavailable fraction, which was used in estimating the bioavailable hepatic blood concentration and also if the fact that there was complete absorption. AUC ratio of the drugs was not calculated based on the \[I\] value and other kinetic parameters such as first order absorption rate K~a~, fraction of systemic clearance of the substrate F~m~, elimination rate, CL~int~ intrinsic clearance etc. Refer section Hepatic Blood Concentrations---Prediction on Inhibition Percentage for formulas.

Discussion {#s4}
==========

Traditional health practitioners often prepare herbal formulations using tea infusions and overnight incubations with alcoholic beverages such as brandy ([@B95]). Hence aqueous and ethanolic extractions of basil were selected for this study. Higher pharmacological activity is generally observed in methanolic, ethanolic, and ethyl acetate extractions ([@B22]). Qualitative analysis is a precursor to analytical fingerprinting of herbal constituents. As per this study, high intensity of flavonoids, phenols, alkaloids, terpenoids, and glycosides were observed in the extracts, some of these compounds being potentially responsible for the aromatic nature of basil oil ([@B59]) and its potential to cause significant interaction with the CYPs. Previous studies have shown the presence of triterpenoid saponins ([@B39]), alkaloids, anthraquinones, saponins, and flavonoids in the methanolic extract as well as glycosides, phenols, phlobatatannins, tannins, and terpenoids in the aqueous extract ([@B29]). In this study more compounds such as phytosteroids and coumarins were also detected, especially in the ethyl acetate extract.

In the HLM screening, except for the aqueous extract (affected only RIF metabolism), all extracts of basil inhibited CYP2B6-mediated metabolism of efavirenz and formation of rifampicin metabolite. There was an increase in rifampicin metabolite formation against the aqueous at extract both concentrations (170% at 200 μg/ml), which could be due to the mechanism of enzyme activation due to the presence of multiple binding sites at the active site of the enzyme ([@B4]; [@B96]); such activations being concentration-dependant. The methanolic extract was strong inhibitor of both pathways, whereas the ethanolic extract was a potent inhibitor of rifampicin pathway with an IC~50~ value of 8.94 μg/ml. Nelfinavir was used as a positive control for this pathway on the assumption that strong CYP inhibitors could also inhibit β-esterases ([@B74]) with an IC~50~ value of 5.44 μg/ml (9.59 μM). The ethanolic extract showed strong inhibition activity in a concentration range from 0-100 μg/ml. At concentrations \>100 μg/ml, the IC~50~ curve did not show a drop in the percentage of remaining activity, unlike the 2-point screening (percentage activity drop from 81.7% at 20 μg/ml to 36.97% 200 μg/ml) indicating the latter to be a relative measurement of the inhibitory effect of an extract at two different concentrations, which would not always correlate with the IC~50~ value obtained. For the positive control ticlopidine the IC~50~ value obtained was within the range reported in earlier studies (12.4--55 μM) ([@B41]; [@B17]). For nelfinavir the IC~50~ was slightly higher than a value of 2.7 μM reported in a previous HLM study done using different assay conditions and bilirubin as the substrate ([@B107]). The aqueous and methanolic extracts had strong TDI effect on CYP2B6, the latter with shift-fold \>7; this effect may be attributed to the formation of reactive secondary metabolites on preincubation with NADPH. The methanolic extract showed weaker TDI on esterase pathway at higher concentration, which could possibly be attributed to the formation of secondary metabolites at higher concentrations, having the potential to interfere with the binding of the active principle in the extract with the enzyme, reducing the TDI effect ([@B34]).

The standard deviation (standard error of the mean) for the data points for few extracts showed high variance in the assays, which could be attributed to external factors that might have interfered with the assays, or the loss of metabolite due to degradation, during the prolonged HPLC runs. All the assays performed were *in vitro*; however in an *in vivo* scenario there are other factors to consider such as concentration differential between tissues, presence of natural barriers such as varying capillary bed permeability, the epithelial membrane barrier, sub-epithelial blood flow, GIT transit time, disease state and dosage form, and intestinal pH ([@B37]; [@B30]).

CYP3A4 is induced more efficiently compared to the other isoenzymes, and is an important criterion for selection in induction screening studies ([@B21]; [@B23]); CYP2B6 has gained recent importance in clinically significant risk assessment induction *in vitro* studies on cryopreserved human hepatocytes, along with CYP3A4 ([@B28]). In this study, all basil extracts moderately induced both the CYPs, more effectively activating the mRNA expression in CYP2B6 in HepG2 cells. *O.basilicum* was previously reported in a study on CYP isoenzymes, as an inhibitor of CYP3A4 ([@B68]). In this study, the basil extracts inhibited CYP3A4 in liver microsomes, and moderately induced mRNA expression in CYP3A4, especially the ethanolic extract. This could be due to the synergistic effects of various phytoconstituents in the extract, or some other potential unidentified inducer molecule within the extract, causing CYP induction.

LC-MS (positive and negative modes) was used to identify the flavonoids, polyphenols, and carboxylic acids in the extracts; these were relatively quantified (reasonable approximations of the relative amounts of the identified compounds present in each extract) using calibration curves set up for quercetin and gallic acid ([@B7]; [@B76]). Rosmarinic acid was a major polyphenol identified; a major component in the aromatic basil essential oil ([@B54]; [@B36]) and a potential inducer of CYPs such as CYP1A, 2B, and 3A ([@B16]). Other major compounds included salvigenin, eupatorin, isocitric, tartaric, chicoric and caftaric acids, the flavonoid rutin, and apigenin-7-O-glucoside, which could have caused the observed inhibition of CYP2B6 and β-esterase activity. Salvigenin was previously reported as a moderate inhibitor of CYP3A enzymes ([@B77]). Caftaric and chicoric acids in *Echinacea*, rutin and apigenin derivatives have been reported to interfere with CYP3A4 activity ([@B10]; [@B18]; [@B53]; [@B93]). Eupatorin inhibits CYP1A2 ([@B71]) and the *in vitro* proliferation of MDA-MB-468 human breast cancer cells that express CYP1A1 ([@B3]). High concentrations of eupatorin, salvigenin and caffeic acids were observed in the ethanolic extract, potentially attributing to its strong inhibition of the rifampicin pathway, compared to the aqueous and methanolic extracts. 12-hydroxyjasmonic acid and fukugetin were the other major identified compounds, which could have added to the inducing capabilities of basil extracts on CYP3A4 mRNA expression along with rosmarinic acid ([@B87]; [@B16]). The calibration curve set up for gallic acid and quercetin was in the range of 6.25-200 mg/L; however some of the identified compounds within the extracts have values above of the range of the calibration curves. The concentrations calculated for these compounds are reasonable approximations of the relative amounts, in comparison to the standard calibrators, and are not absolute quantifications ([@B2]). Various classes of compounds detected are likely to ionize in the MS to vastly different degrees, when compared to the standard calibrators; fold-variations can thus occur in peak areas of these compounds.

As per the FDA guidelines of using model-based predictions ([@B27]) to determine drug interactions, basic to highly dynamic mechanism-based models including physiologically-based pharmacokinetic (PBPK) models have been used to predict DDI in various clinical studies. In this study a basic model was deployed, where GIT concentrations and hepatic blood concentrations were estimated based on single recommended dosages of herbal extracts on the assumption of equal distribution across the entire GIT system. However, factors such as intestinal fluid composition, dosage form, GIT transit time, capillary bed permeability, intestinal pH, tissue distribution and membrane barriers can affect the distribution of the extracts within the human body ([@B26]; [@B37]). The AUCR of the target drug, along with many other factors and parameters such as first order absorption rate K~a~, fraction of systemic clearance of the substrate F~m~, the fraction absorbed after oral administration F~a~, the fraction available after intestinal metabolism F~g~, the elimination rate and the intrinsic clearance CL~int~ were not considered as part of this prediction model. In this study, the predicted percentile of inhibition for the aqueous, methanolic and ethanolic extracts were \> 90% against CYP2B6 and rifampicin pathway, however more mechanistic-dynamic models have to applied considering all the above parameters to predict the probability of *in vivo* HDI of these extracts in the gut assuming that the entire soluble extract interacts with the intestinal CYP enzymes, and competitive inhibition characteristics ([@B27]; [@B56]).

Conclusions {#s5}
===========

The biochemical phytoprofiling of basil extracts showed the presence of bioactive compounds that had the potential to interfere with CYP activity, including phenols, flavonoids, alkaloids, phenols, glycosides, coumarins, phytosterols, tannins and saponins. As per the data reported in this study, hot tea decoction extracts as prepared by the traditional health practitioners, had less inhibitory effect on CYP2B6 and β--esterases when compared to the methanolic and ethanolic extracts. The aqueous and methanolic extracts showed strong reversible and TDI of CYP2B6 while the methanolic and ethanolic extracts inhibited rifampicin metabolism, which may be attributed to the fact that the dried leaves, inflorescence and seeds of this herb had more phytoconstituents such as flavonoids and other secondary metabolites in the composition of the extracts ([@B32]; [@B9]), that had strong potential to modulate CYP activity ([@B60]) or cause toxicity ([@B100]; [@B81]). Previous studies had only reported the inhibitory effect of the ethanolic extract on CYP3A4.

Previous *in vitro* studies have shown that NADPH is a not a prerequisite in the deacetylation process of rifampicin, and the increased formation of 25-*O*-desacetyl rifampicin on addition of NADPH was ascribed to the possible metabolism of rifampicin by NADPH-dependent CYP enzymes ([@B6]; [@B48]). Both nelfinavir and basil caused strong TDI of rifampicin pathway when pre-incubated with NADPH, which suggested that the involvement of other enzymes such as CYPs in the biotransformation of rifampicin, since exogenous supply of NADPH was not mandatory in its deacetylation. In the induction assays in HepG2 cells, the methanolic extract induced CYP2B6 mRNA expression, while the ethanolic extract induced CYP3A4, which could be attributed to the various phytoconstituents in basil such as rutin, rosmarinic acid and salvigenin ([@B20]; [@B52]), and the two different cell systems (HLM and HepG2). Polyphenolic compounds, flavonoids, terpenes, and carboxylic acids were the most observed in basil extracts.

Bioassay-guided fractionation, isolation and identification of the active phytoconstituents in the active extracts and their effect on CYP2B6, 3A4 ad rifampicin metabolism would be a critical step forward. As per the FDA recommendations, analysis of the effects of basil extracts on CYPs---1A2, 2A6, 2D6, 2C9, 2C8, 2C19, and 2E1 is essential. Clinical testing of basil extracts with new *in vitro* models such as "Whole Cell" approach deploying certified human hepatocytes in sandwich-culture with the drug clearance pathways of metabolism and transport, and key regulatory pathways (CAR/PXR) ([@B46]) would also be beneficial in establishing critical data on the effects of basil on cytochrome P450 for further *in vivo* and clinical trial studies.

In conclusion, this study shows that *O.basilicum* (basil) may cause HDI in patients treated with other medications metabolized by CYP2B6 (such as artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone) ([@B106]), or with rifampicin. Caution must therefore be exercised in patients concurrently taking such medications. This finding is clinically significant, considering the fact that it is commonly used as herbal tea, as well as a major ingredient in many food items, herbal formulations and essential oils.
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